You are here: Industry Insights > Besponsa

News List

SMC approves funding for six new therapies on the NHS pharmatimes
July 10, 2018
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
NICE to reassess Pfizer’s leukaemia drug Besponsa pharmatimes
January 03, 2018
The National Institute for Health and Care Excellence will reassess Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia.
Pfizer lashes out at ‘frustrating’ NICE decision on ALL drug Besponsa fiercepharma
August 22, 2017
Pfizer criticized the National Institute of Health and Care Excellence for its decision that its new leukemia drug Besponsa was not cost effective.
Pfizer’s Besponsa gets FDA approval for treatment of B-cell precursor ALL pharmaceutical-technology
August 22, 2017
The US Food and Drug Administration has given approval for Pfizer’s Besponsa (inotuzumab ozogamicin) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
New treatment for adults with relapsed or refractory acute lymphoblastic leukemia biospectrumasia
August 21, 2017
Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.
FDA Approves Besponsa for Relapsed or Refractory ALL americanpharmaceuticalreview
August 18, 2017
The U.S. Food and Drug Administration approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NICE rejects Pfizer’s ALL drug Besponsa pharmatimes
June 15, 2017
to treat some patients with leukaemia on the NHS in England and Wales.